JP5855670B2 - 精神疾患の治療方法 - Google Patents

精神疾患の治療方法 Download PDF

Info

Publication number
JP5855670B2
JP5855670B2 JP2013537287A JP2013537287A JP5855670B2 JP 5855670 B2 JP5855670 B2 JP 5855670B2 JP 2013537287 A JP2013537287 A JP 2013537287A JP 2013537287 A JP2013537287 A JP 2013537287A JP 5855670 B2 JP5855670 B2 JP 5855670B2
Authority
JP
Japan
Prior art keywords
adhd
lurasidone
pharmaceutically acceptable
treatment
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013537287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541582A (ja
JP2013541582A5 (enExample
Inventor
和仁 池田
和仁 池田
健夫 石山
健夫 石山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46020227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5855670(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Priority to JP2013537287A priority Critical patent/JP5855670B2/ja
Publication of JP2013541582A publication Critical patent/JP2013541582A/ja
Publication of JP2013541582A5 publication Critical patent/JP2013541582A5/ja
Application granted granted Critical
Publication of JP5855670B2 publication Critical patent/JP5855670B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013537287A 2010-11-08 2011-05-24 精神疾患の治療方法 Active JP5855670B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013537287A JP5855670B2 (ja) 2010-11-08 2011-05-24 精神疾患の治療方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41108110P 2010-11-08 2010-11-08
US61/411,081 2010-11-08
JP2011033453 2011-02-18
JP2011033453 2011-02-18
PCT/JP2011/062314 WO2012063513A1 (en) 2010-11-08 2011-05-24 Method of treatment for mental disorders
JP2013537287A JP5855670B2 (ja) 2010-11-08 2011-05-24 精神疾患の治療方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015240067A Division JP6470164B2 (ja) 2010-11-08 2015-12-09 精神疾患の治療方法

Publications (3)

Publication Number Publication Date
JP2013541582A JP2013541582A (ja) 2013-11-14
JP2013541582A5 JP2013541582A5 (enExample) 2014-07-10
JP5855670B2 true JP5855670B2 (ja) 2016-02-09

Family

ID=46020227

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537287A Active JP5855670B2 (ja) 2010-11-08 2011-05-24 精神疾患の治療方法
JP2015240067A Active JP6470164B2 (ja) 2010-11-08 2015-12-09 精神疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015240067A Active JP6470164B2 (ja) 2010-11-08 2015-12-09 精神疾患の治療方法

Country Status (6)

Country Link
US (5) US8258139B2 (enExample)
EP (1) EP2638038A4 (enExample)
JP (2) JP5855670B2 (enExample)
CN (1) CN103180315A (enExample)
CA (1) CA2814828C (enExample)
WO (1) WO2012063513A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103565776A (zh) * 2012-07-25 2014-02-12 天津市汉康医药生物技术有限公司 一种稳定的鲁拉西酮胶囊药物组合物
US9732065B2 (en) 2013-05-30 2017-08-15 Sumitomo Dainippon Pharma Co., Ltd. Cyclic aminomethyl pyrimidine derivative
WO2015036972A2 (en) * 2013-09-13 2015-03-19 Florida State University Research Foundation Selective dopamine d4 receptor agonists for treatment of working memory deficits
JP6594351B2 (ja) 2014-06-16 2019-10-23 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 新規中間体を含むアルキル化アリールピペラジン及びアルキル化アリールピペリジン化合物の製造方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
DK36291D0 (da) 1991-03-01 1991-03-01 Lundbeck & Co As H Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser
GB9202915D0 (en) 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
IL110011A (en) 1994-06-13 2004-09-27 Yeda Res & Dev Pharmacological preparations for the treatment of schizophrenia
WO1996014297A1 (en) 1994-11-04 1996-05-17 Sumitomo Pharmaceuticals Company, Limited Novel lactam derivatives
JP3775823B2 (ja) 1995-06-09 2006-05-17 大日本住友製薬株式会社 新規なイミド誘導体
US5688798A (en) * 1995-10-10 1997-11-18 Hoffmann-La Roche Inc. Pyrimidine compounds
AU765603C (en) 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
JP2000281576A (ja) 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd イミド誘導体を含有するプロテオグリカン生成促進剤
AR027134A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de indol.
US20020082283A1 (en) 2000-09-14 2002-06-27 Gliatech, Inc. Nitrogen-containing compounds and their use as glycine transport inhibitors
AU2001286237A1 (en) 2000-09-22 2002-04-02 Sumitomo Pharmaceuticals Company, Limited Oral preparations with favorable disintegration characteristics
MXPA03006003A (es) 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
EP1395257A1 (en) 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
JP4568463B2 (ja) 2001-11-05 2010-10-27 独立行政法人科学技術振興機構 ドレブリンａ発現抑制動物神経細胞及び非ヒトモデル動物
JP4175800B2 (ja) 2001-11-27 2008-11-05 住友化学株式会社 イミド誘導体の製造方法
EP1480629A1 (en) 2002-02-08 2004-12-01 Abbott Laboratories Combination therapy for treatment of schizophrenia
ES2685780T3 (es) 2002-08-22 2018-10-11 Sumitomo Dainippon Pharma Co., Ltd. Agente para el tratamiento de esquizofrenia
KR101113630B1 (ko) 2003-06-23 2012-02-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 노인성 치매 치료제
EP1726952A4 (en) 2004-02-20 2008-06-18 Dainippon Sumitomo Pharma Co METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA
US7122683B2 (en) * 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
EP1891956B1 (en) * 2005-06-13 2012-08-29 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation
TW200812993A (en) 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
EP2094715B1 (en) 2006-10-30 2012-08-29 Sanrx Pharmaceuticals, Inc. Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon
HRP20130041T8 (en) * 2007-04-04 2013-03-31 Merck Sharp & Dohme Corp. Therapeutic agents
JP2008135074A (ja) 2008-02-25 2008-06-12 Fujitsu Ltd 情報公開方法および情報公開装置

Also Published As

Publication number Publication date
US20190022091A1 (en) 2019-01-24
US20130018056A1 (en) 2013-01-17
US10098875B2 (en) 2018-10-16
CA2814828A1 (en) 2012-05-18
US9259423B2 (en) 2016-02-16
JP2013541582A (ja) 2013-11-14
JP6470164B2 (ja) 2019-02-13
WO2012063513A1 (en) 2012-05-18
US20120115879A1 (en) 2012-05-10
EP2638038A1 (en) 2013-09-18
US20160129000A1 (en) 2016-05-12
EP2638038A4 (en) 2014-03-12
US8258139B2 (en) 2012-09-04
US20160193205A1 (en) 2016-07-07
CN103180315A (zh) 2013-06-26
JP2016094440A (ja) 2016-05-26
US9827242B2 (en) 2017-11-28
CA2814828C (en) 2019-09-10

Similar Documents

Publication Publication Date Title
JP2010510314A (ja) 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
US10980802B2 (en) Medicament for treating mental and behavioural disorders
JP6611896B2 (ja) 認知機能および運動機能の増強剤としてのａ２ａアンタゴニスト
JP6470164B2 (ja) 精神疾患の治療方法
CN105764510A (zh) H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途
US20220387396A1 (en) Methods of treating the symptoms of autism spectrum disorder
CN112822997A (zh) 用于治疗孤独症的组合物和方法
RU2635522C2 (ru) Способы поддержания, лечения или улучшения когнитивной функции
JP2019516758A (ja) 不安障害を治療するための（２Ｓ）−１−［４−（３，４−ジクロロフェニル）ピペリジン−１−イル］−３−［２−（５−メチル−１，３，４−オキサジアゾール−２−イル）ベンゾ［ｂ］フラン−４−イルオキシ］プロパン−２−オールまたはその代謝産物
JP2013023459A (ja) 精神疾患治療剤
Possin et al. Parkinsonian dementias
CN106163514B (zh) 注意缺陷和多动性障碍的预防及治疗剂
HK40080588A (en) Methods of treating the symptoms of autism spectrum disorder
HK40080588B (en) Methods of treating the symptoms of autism spectrum disorder
FR2976179A1 (fr) Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent
Pierre et al. Pitolisant hydrochloride

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151209

R150 Certificate of patent or registration of utility model

Ref document number: 5855670

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250